Spectre Bio is an Oxford-based biotechnology company developing Bacteria-Like Particles (BLiPs), safe and programmable microbes that merge the versatility of synthetic biology with the safety of non-replicative systems. By molecularly inactivating cells while retaining their essential cellular structures, Spectre Bio creates a clean biological chassis for applications in vaccines, immunotherapy, and engineered biomanufacturing. The company’s platform enables precise control, intrinsic safety, and broad adaptability across microbial species, positioning Spectre Bio at the forefront of next-generation therapeutic and biotechnological innovation.